Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01228526 · ClinicalTrials.gov registry record
A Multicenter, Prospective, Observational Study With PriMatrix for the Treatment of Neuropathic Diabetic Foot Ulcers
A clinical trial, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- 22
- Enrollment target
NCT01228526: Completed study, sponsored by Integra LifeSciences Corporation.
NCT01228526 is a clinical trial that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01228526 has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of PriMatrix in the treatment of DFUs in subjects without significantly compromised arterial circulation.
Interventions
- DEVICE PriMatrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-09 |
What the finished NCT01228526 record still lists
NCT01228526 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PriMatrix is the first listed.
NCT01228526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01228526 about?
NCT01228526 is a clinical study titled "A Multicenter, Prospective, Observational Study With PriMatrix for the Treatment of Neuropathic Diabetic Foot Ulcers". To evaluate the effectiveness of PriMatrix in the treatment of DFUs in subjects without significantly compromised arterial circulation.
What is the current status of trial NCT01228526?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2010-08. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01228526?
The interventions under investigation include: PriMatrix (DEVICE).
Who is sponsoring clinical trial NCT01228526?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia